Sabre (NASDAQ: SABR) adopts 1-year rights plan after Constellation stake
Rhea-AI Filing Summary
Sabre Corporation adopted a limited-duration shareholder rights plan after noting a substantial accumulation of its stock by Constellation Software. The plan issues one preferred share purchase right for each common share outstanding on March 11, 2026, with an exercise price of $7.00 per one-thousandth of a Series B preferred share.
The rights become exercisable if any person or group acquires at least 15% of Sabre’s common stock, or 20% for certain passive investors, and expire on February 28, 2027. If triggered, other shareholders can buy common stock at a 50% discount or Sabre may exchange each right for one common share, significantly diluting the triggering holder.
The Board can redeem all rights for $0.001 per right before any investor becomes an acquiring person and may exempt specific investors or transactions. Sabre states the plan is not a response to a takeover proposal and is intended to ensure all shareholders receive fair treatment in any control transaction.
Positive
- None.
Negative
- None.
Insights
Sabre adopts a one‑year poison pill to address rapid stock accumulation while preserving board flexibility.
Sabre has put a shareholder rights plan in place that issues one right per common share and becomes active if any holder reaches a 15% ownership threshold, or 20% for certain passive investors. This structure is designed to make large, unsolicited accumulations more expensive via dilution.
The trigger allows non-triggering shareholders to buy stock at a 50% discount or receive shares in exchange, doubling the economic cost to an acquiring person. The Board retains powers to redeem all rights for $0.001 per right before anyone becomes an acquiring person and may exempt particular investors or deals, giving it significant discretion over how the plan operates.
The plan directly responds to Constellation Software’s substantial accumulation of shares but explicitly is not tied to a specific acquisition proposal. It lasts until February 28, 2027, with the Board able to end it earlier, so future disclosures and any changes in Constellation’s position will be important contextual information for investors.